Загрузка...
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AboutScience Srl
2018-10-01
|
| Серии: | AboutOpen |
| Предметы: | |
| Online-ссылка: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/135 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|